Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the divestment of its remaining shareholding in VISUfarma, a pan-European ophthalmic specialty pharmaceutical company, has closed as expected and, as per the press release of 10 July 2020, Nicox has received the funds of €5 million.
Michele Garufi, Chairman and CEO of Nicox, said, ‘We’re delighted with the conclusion of this transaction and the further strengthening of our balance sheet.‘
